TriVascular loans repaid, terminated after acquisition by Endologix

By Wendy Van Sickle

Columbus, Ohio, Feb. 3 – TriVascular Technologies, Inc.’s two term loan agreements were fully repaid and terminated on Wednesday following the company’s acquisition by Endologix, Inc., according to an 8-K filed with the Securities and Exchange Commission.

The terminated agreements include one with Century Medical, Inc. and another with Capital Royalty Partners II LP, Parallel Investment Opportunities Partners II LP, Capital Royalty Partners II—Parallel Fund A LP, Capital Royalty Partners II (Cayman) LP and Capital Royalty Partners II—Parallel Fund B (Cayman) LP.

TriVascular is a medical device company based in Santa Rosa, Calif. Irvine, Calif.-based Endologix develops and makes treatments for aortic disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.